Paul Gisbert  Auwaerter net worth and biography

Paul Auwaerter Biography and Net Worth

Dr. Paul Auwaerter joined the Company’s Board in July 2023. Since 2013, Dr. Auwaerter has been the Sherrilyn and Ken Fisher Professor of Medicine at the Johns Hopkins University School of Medicine, serving as the Clinical Director for the Division of Infectious Diseases and Director of the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases. Dr. Auwaerter has served since 2003 as the Executive Director and Chief Medical Officer of the Johns Hopkins Point of Care-Information Technology (POC-IT) Center, producing the Johns Hopkins ABX (Antibiotic), JH HIV, JH Osler, JH Psychiatry and JH Diabetes Guides. Dr. Auwaerter has also served as Editor-in-Chief of the ABX Guide since 2017. Dr. Auwaerter’s research and clinical interests have led to over 115 publications including improving the diagnosis and care for patients with infectious diseases, specifically Lyme disease, respiratory infections, surgical infections, prosthetic joint infections, Epstein-Barr virus, and fever of unknown origin. He has served as Chair of the Infectious Diseases Society of America Foundation and has been on the Board of Directors of the American Lyme Disease Foundation since 2018. He is a Past President of the Infectious Diseases Society of America (IDSA), the largest professional society worldwide related to infectious diseases, serving from 2017 to 2018. Dr. Auwaerter has been a member of the Board of Directors of the Baltimore Area Council of the Boy Scouts of America and has been awarded the National Distinguished Eagle Scout award. Dr. Auwaerter holds undergraduate and medical degrees from Columbia University and subsequent training in medicine and infectious diseases at Johns Hopkins, where he has been employed since 1988; he also trained in the virology and immunology laboratory of Dr. Diane Griffin.

What is Paul Gisbert Auwaerter's net worth?

The estimated net worth of Paul Gisbert Auwaerter is at least $127 thousand as of October 6th, 2023. Auwaerter owns 5,000 shares of Capricor Therapeutics stock worth more than $127,000 as of December 5th. This net worth approximation does not reflect any other assets that Auwaerter may own. Learn More about Paul Gisbert Auwaerter's net worth.

How do I contact Paul Gisbert Auwaerter?

The corporate mailing address for Auwaerter and other Capricor Therapeutics executives is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. Capricor Therapeutics can also be reached via phone at 310-358-3200 and via email at [email protected]. Learn More on Paul Gisbert Auwaerter's contact information.

Has Paul Gisbert Auwaerter been buying or selling shares of Capricor Therapeutics?

Paul Gisbert Auwaerter has not been actively trading shares of Capricor Therapeutics within the last three months. Most recently, on Friday, October 6th, Paul Gisbert Auwaerter bought 5,000 shares of Capricor Therapeutics stock. The stock was acquired at an average cost of $2.84 per share, with a total value of $14,200.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company's stock, valued at $14,200. Learn More on Paul Gisbert Auwaerter's trading history.

Who are Capricor Therapeutics' active insiders?

Capricor Therapeutics' insider roster includes Paul Auwaerter (Director), and David Musket (Director). Learn More on Capricor Therapeutics' active insiders.

Paul Gisbert Auwaerter Insider Trading History at Capricor Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/6/2023Buy5,000$2.84$14,200.005,000View SEC Filing Icon  
See Full Table

Paul Gisbert Auwaerter Buying and Selling Activity at Capricor Therapeutics

This chart shows Paul Gisbert Auwaerter's buying and selling at Capricor Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Capricor Therapeutics Company Overview

Capricor Therapeutics logo
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Read More

Today's Range

Now: $25.40
Low: $23.05
High: $30.60

50 Day Range

MA: $7.19
Low: $4.60
High: $29.96

2 Week Range

Now: $25.40
Low: $4.30
High: $40.37

Volume

8,600,250 shs

Average Volume

5,002,246 shs

Market Capitalization

$1.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61